SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Hjorth Hansen Henrik) ;pers:(Simonsson Bengt)"

Sökning: WFRF:(Hjorth Hansen Henrik) > Simonsson Bengt

  • Resultat 1-10 av 13
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Baccarani, Michele, et al. (författare)
  • Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia : a European LeukemiaNet Study
  • 2009
  • Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 113:19, s. 4497-4504
  • Tidskriftsartikel (refereegranskat)abstract
    • Imatinib mesylate (IM), 400 mg daily, is the standard treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML). Preclinical data and results of single-arm studies raised the suggestion that better results could be achieved with a higher dose. To investigate whether the systematic use of a higher dose of IM could lead to better results, 216 patients with Ph(+) CML at high risk (HR) according to the Sokal index were randomly assigned to receive IM 800 mg or 400 mg daily, as front-line therapy, for at least 1 year. The CCgR rate at 1 year was 64% and 58% for the high-dose arm and for the standard-dose arm, respectively (P = .435). No differences were detectable in the CgR at 3 and 6 months, in the molecular response rate at any time, as well as in the rate of other events. Twenty-four (94%) of 25 patients who could tolerate the full 800-mg dose achieved a CCgR, and only 4 (23%) of 17 patients who could tolerate less than 350 mg achieved a CCgR. This study does not support the extensive use of high-dose IM (800 mg daily) front-line in all CML HR patients. This trial was registered at www.clinicaltrials.gov as #NCT00514488.
  •  
2.
  • Baccarani, Michele, et al. (författare)
  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013
  • 2013
  • Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 122:6, s. 872-884
  • Forskningsöversikt (refereegranskat)abstract
    • Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed prior and new studies to update recommendations made in 2009. We recommend as initial treatment imatinib, nilotinib, or dasatinib. Response is assessed with standardized real quantitative polymerase chain reaction and/or cytogenetics at 3, 6, and 12 months. BCR-ABL1 transcript levels <= 10% at 3 months, <1% at 6 months, and <= 0.1% from 12 months onward define optimal response, whereas >10% at 6 months and >1% from 12 months onward define failure, mandating a change in treatment. Similarly, partial cytogenetic response (PCyR) at 3 months and complete cytogenetic response (CCyR) from 6 months onward define optimal response, whereas no CyR (Philadelphia chromosome-positive [Ph1]>95%) at 3 months, less than PCyR at 6 months, and less than CCyR from 12 months onward define failure. Between optimal and failure, there is an intermediate warning zone requiring more frequent monitoring. Similar definitions are provided for response to second-line therapy. Specific recommendations are made for patients in the accelerated and blastic phases, and for allogeneic stem cell transplantation. Optimal responders should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved. (Blood. 2013; 122(6):872-884)
  •  
3.
  •  
4.
  • Hjorth-Hansen, Henrik, et al. (författare)
  • Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
  • 2015
  • Ingår i: European Journal of Haematology. - : Wiley. - 1600-0609 .- 0902-4441. ; 94:3, s. 243-250
  • Tidskriftsartikel (refereegranskat)abstract
    • We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100mg QD or imatinib 400mg QD and report outcome as an intention-to-treat analysis with 36months follow-up. Early cytogenetic and molecular responses were superior in the dasatinib group, with a tendency that imatinib patients caught up with time. For instance, MR3.0 was reached at 3months in 36% vs. 8% (P=0.02), at 12months in 81% vs. 46% (P=0.02) and at 18months in 73% vs. 65% (n.s.) of the patients in the two groups. In contrast, MR4.5 was consistently superior in the dasatinib group at all time points from 6months onwards, reaching 61% vs. 21% (P<0.05) at 36months. Sixty-four vs. 71% of the patients in the dasatinib and imatinib arms, respectively, remained on assigned drug. Dasatinib dose was frequently reduced, but with maintained excellent effect. One imatinib patient progressed to blastic phase, but no CML-related deaths occurred. In conclusion, our data compare favourably with those of the dasatinib registration study, DASISION. The fast and deep molecular responses induced by dasatinib compared with imatinib may be exploited to increase the proportion of patients who can achieve a treatment-free remission after treatment discontinuation.
  •  
5.
  • Koskenvesa, Perttu, et al. (författare)
  • Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response
  • 2014
  • Ingår i: European Journal of Haematology. - : Wiley. - 0902-4441 .- 1600-0609. ; 92:5, s. 413-420
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives Previous studies indicate that 40-50% of patients with chronic myeloid leukemia in prolonged complete molecular remission may discontinue imatinib therapy without imminent relapse. The combination of pegylated interferon-alpha (Peg-IFN-alpha 2b) and imatinib may increase the rate of successful discontinuation. Methods In this pilot study, we prospectively stopped imatinib from patients (n=12) who had achieved major molecular response (MMR) after >= 12months of treatment with either imatinib or imatinib+Peg-IFN-alpha 2b. Molecular monitoring was carried out monthly for BCR-ABL1. In addition, analyses of lymphocyte immunophenotype, function, and plasma cytokines were performed. Results In the monotherapy group, 5/6 patients lost MMR within 4months. One patient remains to date in MR4.0 61months after discontinuation. In the combination therapy group, 2/6 patients relapsed within 4months while still receiving Peg-IFN-alpha 2b. Four of six patients were able to discontinue both treatments, but three of these patients relapsed after 3months. One patient is still in sustained MR4.0 at 58months off all treatment. All relapsed patients re-responded to imatinib. The two successfully discontinued patients had either an increased number of NK-cells or functionally active T-cells. Conclusions A higher frequency of relapsed patients in our study in comparison with other studies may be due to the shorter duration of imatinib treatment prior to discontinuation. However, in selected patients with an active immune system, even a short duration of TKI therapy (<2yr) may allow for therapy discontinuation but this needs to be confirmed in larger prospective studies.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 13
Typ av publikation
konferensbidrag (5)
tidskriftsartikel (5)
forskningsöversikt (2)
annan publikation (1)
Typ av innehåll
refereegranskat (12)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Hjorth-Hansen, Henri ... (13)
Porkka, Kimmo (10)
Mustjoki, Satu (10)
Gedde-Dahl, Tobias (7)
Koskenvesa, Perttu (7)
visa fler...
Ehrencrona, Hans (6)
Richter, Johan (6)
Stenke, Leif (6)
Malm, Claes (5)
Weiss-Bjerrum, Ole (5)
Ohm, Lotta (5)
Remes, Kari (5)
Stentoft, Jesper (5)
Kairisto, Veli (4)
Dybedal, Ingunn (4)
Majeed, Waleed (4)
Markevarn, Berit (4)
Suominen, Merja (4)
Josefsen, Dag (3)
Fioretos, Thoas (3)
Olofsson, Tor (3)
Barbany, Gisela (3)
Hovland, Randi (3)
Lassen, Carin (3)
Olsson-Strömberg, Ul ... (3)
Nagler, Arnon (3)
Lanng Nielsen, Johan (3)
Markevärn, Berit (3)
Söderlund, Stina (3)
Olsson-Stromberg, Ul ... (3)
Rapakko, Katrin (3)
Rasanen, Anu (3)
Sinisalo, Marjatta (3)
Höglund, Martin (2)
Baccarani, Michele (2)
Rosti, Gianantonio (2)
Pane, Fabrizio (2)
Saglio, Giuseppe (2)
Martinelli, Giovanni (2)
Olsson, Karin (2)
Lindblom, Anders (2)
Christiansson, Lisa (2)
Myhr-Eriksson, Krist ... (2)
Flogegard, Max (2)
Kreutzman, Anna (2)
Gjertsen, Bjorn (2)
Bjoreman, Mats (2)
Vakkila, Jukka (2)
Gruber, Franz (2)
visa färre...
Lärosäte
Uppsala universitet (8)
Linköpings universitet (5)
Lunds universitet (5)
Karolinska Institutet (3)
Umeå universitet (2)
Språk
Engelska (13)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (8)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy